These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9628087)

  • 1. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder.
    Moore GJ; MacMaster FP; Stewart C; Rosenberg DR
    J Am Acad Child Adolesc Psychiatry; 1998 Jun; 37(6):663-7. PubMed ID: 9628087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine.
    Rosenberg DR; MacMaster FP; Keshavan MS; Fitzgerald KD; Stewart CM; Moore GJ
    J Am Acad Child Adolesc Psychiatry; 2000 Sep; 39(9):1096-103. PubMed ID: 10986805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD.
    Bolton J; Moore GJ; MacMillan S; Stewart CM; Rosenberg DR
    J Am Acad Child Adolesc Psychiatry; 2001 Aug; 40(8):903-6. PubMed ID: 11501689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression.
    Saxena S; Brody AL; Ho ML; Zohrabi N; Maidment KM; Baxter LR
    Am J Psychiatry; 2003 Mar; 160(3):522-32. PubMed ID: 12611834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain neurochemistry in unmedicated obsessive-compulsive disorder patients and effects of 12-week escitalopram treatment:
    Parmar A; Sharan P; Khandelwal SK; Agarwal K; Sharma U; Jagannathan NR
    Psychiatry Clin Neurosci; 2019 Jul; 73(7):386-393. PubMed ID: 30973183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine.
    Gilbert AR; Moore GJ; Keshavan MS; Paulson LA; Narula V; Mac Master FP; Stewart CM; Rosenberg DR
    Arch Gen Psychiatry; 2000 May; 57(5):449-56. PubMed ID: 10807485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study.
    Hansen ES; Hasselbalch S; Law I; Bolwig TG
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):1-10. PubMed ID: 12057027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder.
    el Mansari M; Bouchard C; Blier P
    Neuropsychopharmacology; 1995 Oct; 13(2):117-27. PubMed ID: 8597523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial.
    Denys D; Van Nieuwerburgh F; Deforce D; Westenberg HG
    J Clin Psychiatry; 2007 May; 68(5):747-53. PubMed ID: 17503984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder.
    Saxena S; Brody AL; Maidment KM; Dunkin JJ; Colgan M; Alborzian S; Phelps ME; Baxter LR
    Neuropsychopharmacology; 1999 Dec; 21(6):683-93. PubMed ID: 10633474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
    Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
    BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder.
    Humble M; Bejerot S; Bergqvist PB; Bengtsson F
    Biol Psychiatry; 2001 Feb; 49(4):360-8. PubMed ID: 11239907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine.
    Ninan PT
    Psychopharmacol Bull; 2003; 37 Suppl 1():89-96. PubMed ID: 14566204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series.
    Van Ameringen M; Mancini C; Patterson B; Bennett M
    Depress Anxiety; 2006; 23(1):1-5. PubMed ID: 16178009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
    Geller DA; Biederman J; Stewart SE; Mullin B; Farrell C; Wagner KD; Emslie G; Carpenter D
    J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S19-29. PubMed ID: 12880497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder.
    Rosenberg DR; Stewart CM; Fitzgerald KD; Tawile V; Carroll E
    J Am Acad Child Adolesc Psychiatry; 1999 Sep; 38(9):1180-5. PubMed ID: 10504818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder.
    Hollander E; Dell'Osso B
    Int Clin Psychopharmacol; 2006 May; 21(3):189-91. PubMed ID: 16528143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.
    Zohar J; Judge R
    Br J Psychiatry; 1996 Oct; 169(4):468-74. PubMed ID: 8894198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.